Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 4

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 number of shares of common stock held by such shareholder immediately
prior to the Reverse Split, divided by (ii) 1,500, and then rounded up to the nearest whole number. No fractional shares were issued,
and no cash or other consideration was paid to any shareholder. Instead, the Company issued one whole share of the post-Reverse Stock
Split common stock to any shareholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. Except
for the Company’s historical financial statements and unless otherwise stated, all option, share, and per share information gives
effect to the Reverse Stock Split.

E. DERIVATIVE LIABILITY

The
Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “ Derivatives
and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained
in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change
in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying
amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model.

The
Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded
derivative is recognized as of March 31, 2025 utilized the following inputs:

SCHEDULE
OF DERIVATIVE LIABILITY ON CONVERTIBLE NOTES USING BLACK SCHOLES PRICING MODEL

  Schedule of Derivative liability                          
  Risk Free Interest Rate               4.04                
  Expected Term                         0.43 – ( 4.91) Yrs  
  Expected Volatility                   1170.04             
  Expected Dividends                    -                   

F. INCOME TAXES

The
Company accounts for income taxes using the liability method prescribed by ASC 740, “ Income Taxes.” Under this method, deferred
tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities
using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation
allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or
all, of the deferred tax assets will not be realized. The effect